Gufic Biosciences gets nod from NMPA for PRILOCAINE API

17 Jun 2023 Evaluate

Gufic Biosciences (Gufic) has received approval from National Medical Products Administration (NMPA), China for its product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the said product in China and explore Chinese market. 

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

347.25 -4.20 (-1.20%)
17-Dec-2025 12:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.90
Dr. Reddys Lab 1276.50
Cipla 1493.75
Zydus Lifesciences 919.10
Lupin 2116.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×